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factors, pretransplant disease status and factors apart from
leukemia could affect the success of allo-SCT. It is still un-
certain that allo-SCT in CR1 has superior efﬁcacy especially
for those patients who have cytogenetically standard risk.
The optimization of supportive care in last 2 decades
decreased early transplant related mortality substantially. In
this intent-to-treat, single center, retrospective study we
analyzed 40 consecutive AML patients who underwent allo-
SCT between January 2011 and November 2013 at our center
to determine the role of allo-SCT in CR1 or beyond. Patients
were evaluated for overall survival (OS), disease free survival
(DFS), early (30-100 day) and late (101-365 day) transplant
related mortality (TRM). Survival was estimated using the
KaplaneMeier method, and the log-rank test was used to
compare survival curves among variables. Median age was
48 years (19-64 y). Among those patients who had cytoge-
netic data (28 patient, 70%), 12 (30%) were in high-risk
category. Median time from diagnosis to allo-HCT was 6.5
months (2-54 months). Median follow-up period for living
patients was 419 days (105-857). Status at tx: 24 patients
(60%) in CR1, 12 patients (30%) in CR2 and 4 patients (10%)
who received myeloablative (Bu16-CY120) (n¼32, 80%) or
reduced-intensity regimens (Flu150-Bu8)(n¼8, 20%). Donors
were matched related for 32 patients (80%), unrelated for 7
patients (17.5%) and haploidentical for 1 patient (2.5%). All
but 2 patients (95%) received PBSC. All patients received
primary antifungal prophylaxis. Overall, TRM at day 30 and
100 were 7.5% (n¼3) and 10% (n¼4), respectively. Late death
(>100 days) was observed in 7 patients (17.5%) and 3 of them
were related to allo-SCT. Grade 2-4 aGVHD was seen in 20
(50%) patients and chronic extensive GVHD in 8 patients
(20%). Of those 24 patients who underwent allo-HCT in CR1,
18 patients (75%) were still in remission without any sign of
disease. Nine of 16 patients (56.3%) who underwent allo-SCT
beyond CR1 lost due to relapsed leukemia. Survival analysis
revealed superior OS between patients in CR1 (median 901
days) and beyond CR1 (median 202 days) (log-rank, OS
p¼0.003)(Fig 1). For disease free survival we have seen the
same proﬁle (p¼0.007). In CR1 patients (n¼24) univariate
analysis revealed no impact of standard-risk cytogenetics,
high HCT-CI (2), high WBC at dx (>30k), sex (F to M), ABO
mismatch and double induction for CR achievement. The
only adverse factor for short OS in CR1 was past history of
invasive fungal infection pre allo-SCT (p¼0.038, 901d vs
553d). Allogeneic HCT in AML patients should be undertakenin CR1 with matched sibling donor. Pre-tx invasive fungal
infection was the only worst predictive factor for OS in CR1.382
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In the Germanmulticentre ALL studies, all patients (pts) with
induction failure or after relapse are candidates for allogeneic
SCT. We report here our single center data on 57 pts. Median
age was 28 years (18-57). ALL subtypes were: Ph+ ALL (n¼8),
B-lineage (pre B, B, pro B) (n¼36), T lineage (pre T, mature T,
thymic) (n¼13). Before conditioning, 12/57 pts had induction
failure, 31/57 pts were in CR2, 8/57 pts in 2. relapse, and 6/57
pts in CR3.Median duration of CR1 (n¼45)was 21months (2-
107), CR2 (n¼14) was 4 months (1-168). Pts with induction
failurehadat leastGMALL, Induction I+II followedby2 further
protocols. Induction chemotherapy of relapse varied and
consisted of the GMALL protocol, ALL relapse protocol, Ida-
FLAG, CLAEG, GIMEMA protocol, and local therapy of extra-
medullary leukemia. 27/37 pts transplanted in CR2 or CR3
reached CR after 1. chemotherapy, 7 after 2. chemotherapy,
and 3 after 3. chemotherapy. Conditioning regimen was
myeloablative (12Gy TBI + Cy/ VP16) in 49 pts, reduced in-
tensity conditioning (8Gy TBI or Flu+Bu+ATG) in 7 pts, and
Treosulfan in 1 pt. Donors were matched unrelated donors
(MUD) in 35 pts, HLA identical siblings in 21 pts, and a HLA-
compatible child in 1 pt. GvHD prophylaxis was mainly CSA/
MTX, since 2005 ATG was given in MUD additionally.
Results: 13/57 pts (23%) are alive in continuous CR (CCR).
The median follow-up after allo-SCT for surviving pts is
155 months (5-222). 26/57 pts died due to relapse, 18/57
pts due to treatment-related mortality (TRM), mainly
GvHD and/or infections. Probability of leukemia free sur-
vival (LFS) at 48 months is 25% for pts with induction
failure, 30% for pts in CR2, 12% for pts in second relapse,
and 33% for pts in CR3.
Conclusions: Adult ALL pts after 1. relapse can only be cured
by allo-SCT, but the relapse rate is high. The same is true for
ALL pts with induction failure/primary refractory. Perspec-
tive in the GMALL studies is to transplant pts with molecular
failure before hematologic relapse occurs. In patients with
induction failure, up to now, allo-SCT is the only chance of
cure. In B-lineage ALL, Blinatumomab may improve the re-
sults as bridging to allo-SCT.383
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